Selvita is the first contract research organisation (CRO) to license a Chemical Protein Stability Assay developed and patented by Medicines Discovery Catapult (MDC) to help identify and prioritise drug candidates faster.
Qubit Pharmaceuticals, a deeptech company specialising in the discovery of new drug candidates, unveils the "world’s most advanced" quantum AI model to unlock an entirely new range of therapeutics.
Aptamer Group presented new data on its Optimer therapeutic delivery vehicle for liver fibrosis at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in New Orleans, LA (13-17 May 2025).
Thermo Fisher Scientific has introduced the Applied Biosystems MagMAX Pro HT NoSpin Plasmid MiniPrep Kit to address the critical need for rapid and automated plasmid DNA isolation, enabling scientists to conduct small-scale experiments quickly.
Aenova, a contract development and manufacturing organisation (CDMO) in the global pharmaceutical supply chain, announces the launch of its Aenovation program.
HepaRegeniX announced that the company’s co-founder, Prof. Dr. med. Lars Zender, gave the Karl Wilhelm von Kupffer Basic Science plenary talk at the 2025 European Association for the Study of the Liver (EASL) Congress.
Philipp Koellinger, CEO and co-founder of open science pioneer DeSci Labs, explains the reshaping of the scientific publishing landscape and explores what it means for scientists worldwide.
Aptamer Group, a developer of next-generation synthetic binders, has announced the adaptation of the Optimer-based test for Alzheimer’s disease into an Enzyme-Linked Immunosorbent Assay (ELISA).
The Novo Nordisk Foundation has announced the latest edition of its annual Challenge Programme, where for the first time it is inviting researchers from outside Denmark, in the European Schengen area, Ireland and the UK.
Metrion Biosciences, a preclinical contract research organisation (CRO), has announced the launch of its validated, high-throughput NaV1.9 screening assay to advance discovery and development of novel pain therapeutics.
CN Bio, a provider of Organ-on-a-chip systems and solutions that accelerate drug discovery and development workflows, has announced the establishment of a strategic partnership with Pharmaron, a premier R&D service provider for the industry.
